Tilray: Fourth Quarter Consensus Estimates

Tilray (TSX: TLRY) (NASDAQ: TLRY) will be reporting its fourth quarter financial results on July 28 before the market opens. Analysts have a consensus $17.77 12-month price target on the company, via a total of 20 analysts, with 2 analysts having strong buy ratings. 3 analysts meanwhile have buy ratings, 14 have hold ratings and a single analyst has a sell rating on the company. The street high comes from Roth Capital with a $25 price target, and the lowest target sits at $1.27 from GLJ Research.

10 analysts have revenue estimates for the fourth quarter. The mean revenue estimate between all 10 analysts is $146.19 million; this number has been revised upwards from $71.20 million at the start of the year. The highest revenue estimate is $175.4 million, while the lowest is $107.62 million.

Onto EBITDA estimates, there are currently 7 analysts who have fourth-quarter EBITDA estimates. The mean is currently $5.81 million, with this number being flat since the start of the year. The street high estimate currently sits at $11.7 million in EBITDA and the lowest is -$2.83 million.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why the Market May Be Misreading Iran | David Woo

Why US Fertilizer Supply Could Matter a Lot More Now | Pat Varas – Sage Potash

Roscan Gold: Mali Discount Hits Kandiole PEA

Recommended

Total Metals Secures High Grade Critical Minerals Property In Northwestern Ontario

Discovery at Luis Hill Prompts Acceleration of Phase 2 Program for Questcorp

Related News

AMD: Analysts Raise Estimates, Markets Shrug Following Earnings

Advanced Micro Devices (NASDAQ: AMD) opened 3% higher but ultimately closed down 1.4% the day...

Friday, April 30, 2021, 03:41:00 PM

Canaccord Raises Mind Medicine’s Price Target To $2.00 Following Financing

This morning, Canaccord Genuity raised its 12-month price target on Mind Medicine (NEO: MMED) from...

Monday, November 2, 2020, 10:45:02 AM

Village Farms: Raymond James Speculates On Acquisition By Canopy Growth

This morning, Raymond James sent out a note to investors giving a scenario analysis where...

Thursday, December 24, 2020, 12:18:23 PM

Cronos Group: Canaccord, PI Reiterate Ratings, Adjust Revenue Estimates

Cronos Group (TSX: CRON) (NASDAQ: CRON) reported its second quarter financials on August 6 pre-market,...

Sunday, August 9, 2020, 04:20:00 PM

Canaccord: Meta Platforms’ Near Term Headwinds Are Priced In

On October 25th, Facebook (NASDAQ: FB), now called Meta Platforms, reported their 2021 third quarter...

Thursday, November 4, 2021, 05:08:00 PM